In vitro study to evaluate the sensitivity to daptomycin among gram positive clinical isolates

Citation metadata

Date: January-March 2012
From: Indian Journal of Medical Microbiology(Vol. 30, Issue 1)
Publisher: Elsevier B.V.
Document Type: Article
Length: 738 words
Lexile Measure: 2080L

Document controls

Main content

Article Preview :

Byline: K. Padmaja, P. Umabala, KSRK. Prasad, V. Lakshmi

Dear Editor,

Gram positive bacteria are a major cause of serious infections such as complicated skin and soft tissue infections, bacteraemia and infective endocarditis. Infecting organisms include resistant pathogens such as methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci (VRE) which have become a major concern over the last decade. Antibiotics such as glycopeptides (vancomycin and teicoplanin) and the oxazolidinone (linezolid) are being effectively used for treatment of such infections. However, the growing resistance among these organisms indicates a need for newer antimicrobials. [sup][1]

Daptomycin, a fermentation product produced by Streptomyces roseosporus , a cyclic lipopeptide, is a potential novel antibiotic for the treatment of skin and soft tissue Gram positive infections. [sup][2] In vitro time kill studies found Daptomycin to be rapidly bactericidal against the majority of organisms tested, killing 99.9% of bacteria within 6 h. [sup][1] This novel antimicrobial was approved by the United States Food and Drug administration (US-FDA) in 2003, to be administered intravenously at the dose of 4 mg/kg of body weight/day for the treatment of complicated skin and soft...

Source Citation

Source Citation   

Gale Document Number: GALE|A281747264